Vital Transformation understands the implications of new medical procedures, technologies and policies. We measure their impact on current clinical practices in close collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders. Vital Transformation has presented or participated in conferences sponsored by The Royal College of Physicians, European Health Forum Gastein, The European Commission, London Genetics, The European Science Foundation, The European Microelectronics Summit, and others. Our Vital Transformation branded round-tables, webinars, and conferences are often oversubscribed, and are regularly presented in partnership with global thought-leaders and organisations.
OUR RESEARCH
Whole-Body Magnetic Resonance Angiography (WBMRA) as a tool for driving efficiency in the cost and treatment of Claudication Comorbities
12th September, 2013
Abstract
Whole-Body Magnetic Resonance Angiography (WBMRA) consists of a contrast-enhanced Magnetic Resonance Angiogram (MRA) scan of the entire body in a single step. In the diagnosis of cardiovascular co-morbidities in Peripheral Arterial Disease (PAD), the utilization of WBMRA can streamline the diagnostic process by minimizing the usage of MRA, CT, and Angiograms. In this work, the potential cost savings to the hospital by using WBMRA in PAD are modeled based on collected data that accounts for all interventions in the radiological department of a set of 50 patients with Claudication in the period 2008–2012 at Ninewells Hospital (NHS Tayside).
Innovation Requires a New Regulatory Framework to Improve Research and Development of New Medical Therapies
20th June, 2013
By Duane Schulthess
For targeted medicines, the current processes of regulatory evaluation, decision frameworks and delivery systems are limiting the implementation of new, better therapies. A healthcare ecosystem designed to enable innovation must also support R&D that is cost effective for all stakeholders and make-good on the promise that innovative medicines can effectively deliver the right prevention and treatment to the right patient at the right time.
Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?
September, 2012
Abstract
This study is a cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome – a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of €4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (−59%), Angioplasty (−59%), Bypass (−17%), Medication (−14%) and Rehabilitation (−13%).
PODCASTS
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
Our clients include many of the world’s leading health care organisations.
